RETRANSMISSION: HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for GrowthThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for GrowthThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery TechnologiesOncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk. The company’s approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities.
How Advanced Drug Delivery Could Improve Existing Cancer TreatmentsBioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (
NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (
NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than…
How Advanced Drug Delivery Could Improve Existing Cancer TreatmentsAUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (
NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (
NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!A number of actively traded small-cap and growth stocks are drawing increased investor attention as momentum continues building across sectors tied to AI infrastructure, biotechnology, GLP-1 healthcare, vaccines, high-performance computing, and digital infrastructure. Names currently trading actively include ENDRA Life Sciences Inc. (
NASDAQ: NDRA), Sunshine Biopharma Inc. (
NASDAQ: SBFM), GeoVax Labs Inc. (
NASDAQ: GOVX), HIVE Digital Technologies Ltd. (
NASDAQ: HIVE), and Sphere 3D Corp. (
NASDAQ: ANY).
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor AwarenessENDRA Life Sciences Inc. (
NASDAQ: NDRA) is gaining increasing investor attention as the company advances its TAEUS® Liver imaging platform while simultaneously evaluating strategic alternatives aimed at maximizing shareholder value.
RETRANSMISSION: HIVE's BUZZ HPC Announces 320 MW Sovereign AI Infrastructure in Greater Toronto AreaToronto, Ontario--(Newsfile Corp. - May 18, 2026) - HIVE Digital Technologies Ltd. (TSX: HIVE) (
NASDAQ: HIVE) (FSE: YO0), through its...
HIVE's BUZZ HPC Announces 320 MW Sovereign AI Infrastructure in Greater Toronto AreaToronto, Ontario--(Newsfile Corp. - May 18, 2026) - HIVE Digital Technologies Ltd. (TSX: HIVE) (
NASDAQ: HIVE) (FSE: YO0), through its...
RETRANSMISSION: HIVE's BUZZ Starts Building A Digital Superhighway for Eastern Canada's First Sovereign AI FactoryVancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (
NASDAQ: HIVE) (FSE: YO0) (BVC:...
HIVE's BUZZ Starts Building A Digital Superhighway for Eastern Canada's First Sovereign AI FactoryVancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (
NASDAQ: HIVE) (FSE: YO0) (BVC:...
HIVE Digital Announces Up-Listing to TSX and Provides Corporate UpdateThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
HIVE Digital Announces Closing of Private Offering of US$115 Million of 0% Exchangeable Senior Notes Due 2031San Antonio, Texas--(Newsfile Corp. - April 21, 2026) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (
NASDAQ: HIVE) (BVC: HIVECO) (the...
HIVE Digital Announces Upsizing and Pricing of Private Offering of US$100 Million of 0% Exchangeable Senior Notes Due 2031This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
HIVE Digital Announces Private Offering of US$75 Million of Exchangeable Senior Notes due 2031This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
HIVE Digital Technologies Reaches AI Cloud Milestone in Paraguay, Powers Columbia University LLM Research from New York to AsunciónThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
HIVE's BUZZ HPC Expands Data Center Footprint into British Columbia with 4 Times Growth in Liquid-Cooled AI Data Center CapacityThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
RETRANSMISSION: AMC Robotics and HIVE Announce Collaboration to Advance AI-Driven Robotics Compute InfrastructureThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
AMC Robotics and HIVE Announce Collaboration to Advance AI-Driven Robotics Compute InfrastructureNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), an AI-driven robotics solutions provider, and HIVE Digital Technologies (“HIVE”) (TSX.V: HIVE) (Nasdaq: HIVE) (FSE: YO0) (BVC: HIVECO), a global leader in sustainable digital infrastructure and AI compute, today jointly announced a strategic collaboration focused on advancing next-generation AI-driven robotics applications and scalable infrastructure capabilities.
AMC Robotics and HIVE Announce Collaboration to Advance AI-Driven Robotics Compute InfrastructureThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
RETRANSMISSION: HIVE Provides Results from Shareholder MeetingThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025...
